{"symbol":"BMY","fiscalQuarter":"Q3-2013","reportDate":"2013-10-23","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q3-2013","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Down 1.55%","keyNumbers":[{"metric":"EPS","actual":"$0.46","expected":"N/A","surprise":"+5.02%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on delivering value through our pipeline."],"summary":"Management expressed satisfaction with the EPS results, highlighting the importance of their ongoing projects. They emphasized a commitment to maintaining operational efficiency."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report showed a positive surprise in EPS, which indicates better-than-expected profitability. However, the stock fell 1.55% on the day, likely due to the lack of revenue data and forward guidance, leaving investors uncertain about future performance. The cautious tone from management may have also contributed to the stock's decline.","metaDescription":"Bristol Myers Squibb (BMY) Q3 2013 earnings: EPS beat by 5.02%. Stock down 1.55%. Full breakdown."}}